10-Year Follow-Up: Pembrolizumab Outshines Ipilimumab in Advanced Melanoma
Long-term study shows pembrolizumab's superior efficacy over ipilimumab for advanced melanoma patients.
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
1 article
New Hope for BTK Inhibitor Intolerant Patients: Pirtobrutinib Shows Promise in B-Cell Malignancies
Pirtobrutinib demonstrates efficacy and tolerability in patients with B-cell cancers who couldn't tolerate other BTKis.